The microbiome market comprises of sales of bioactive molecules and linked products which are utilized as immunotherapeutic agents in pharmaceuticals industry. The microbiome market is principally engaged in the improvement and sales of such bioactive products which are utilized as immunotherapy for a wide variability of conditions such as infectious syndromes, endocrine & metabolic disorders, inflammatory conditions, cancer, irritable bowel syndrome, neurological syndromes, hematological disorders and cardiovascular sickness as well.
According to the report analysis, ‘Microbiome Global Market Report 2020-30: Covid 19 Impact and Recovery’ states that during January 2020, Psomagen-Macrogen Consortium obtained uBiome for a deal amount of USD 7.05 Million. The deal contains of patent portfolio of 246 patents (60 enumerated US patents and 186 applications), approximately 300,000 sample data and laboratory equipment. The Psomagen has become a foremost player in the microbiome segment with this acquisition.
Additionally, the worldwide microbiome market is predicted to reduce from USD 0.34 billion during 2019 to USD 0.27 billion throughout 2020 at a compound annual growth rate (CAGR) of -20%. The deduction is mainly owing to the aim on Covid-19 outbreak and its treatment around the globe, resulting in patients of other sicknesses delaying their episodes of care. The market is then projected to recover and reach USD 0.58 billion during 2023 at a CAGR of 14%. North America was the chief region in the microbiome market during 2019. The microbiome market around Asia Pacific is reviewed to register the maximum CAGR during 2019-2023.
Although, the augmented number of lifestyle syndromes such as diabetes, cancer, depression and several others in the historical duration has positively affected the microbiome market. Lifestyle transform the influences the micro flora inside at every stage of life leading to lifestyle sicknesses and thus fluctuating the microbiome can support in decreasing such lifestyle diseases. Around the globe from 1975 the obesity population has approximately tripled and now 30% of the populace is obese. During recent studies, Fecal Microbiome Transplantation has presented the beneficial results in treating patients with obesity and also diabetes. Thus, growing lifestyle transformations which lead to lifestyle diseases support drive the growth of this market.
Nonetheless, there are several major players in the microbiome market such as Enterome Bioscience, Vedanta Biosciences Inc., Osel Inc., Synlogic Inc., Second Genome, Seres Therapeutics, Synthetic Biologics Inc., uBiome, Inc., Metabiomics Corporate, Rebiotix Inc for leading the highest market growth and dominating the handsome value of market share around the globe.
Not only has this, the technological advancements such as software programs enable easy analyzing of the metagenomic datasets connected to the genes of the microbiota along with the user-friendliness, effortlessness of access and with ability to deliver the graphical representation for convenient and quick understanding of the analyzed data. Specialized software programs prevail for analyzing the metagenomic data are FastQC, Fastx-Toolkit, PRINSEQ, and several others. Thus, technological improvements and innovative methods aid in growth of the human microbiome market. Therefore, in the near years, it is predicted that the market of microbiome will increase around the globe more effectively over the upcoming years.
For More Information, Click on the Link Below:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
